$MREO SEC Filings

Filed On	Filing
19 Aug 2026	8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
14 Aug 2026	SCHEDULE 13G/A
11 Aug 2026	10-Q
11 Aug 2026	8-K: Results of Operations and Financial Condition
11 Aug 2026	8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
15 May 2026	SCHEDULE 13G/A
14 May 2026	SCHEDULE 13G
14 May 2026	8-K: Submission of Matters to a Vote of Security Holders
12 May 2026	8-K/A: Results of Operations and Financial Condition London, May 12, 2026 – Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced financial results for the first quarter ended March 31, 2026...
12 May 2026	10-Q
12 May 2026	8-K: Completion of Acquisition or Disposition of Assets
09 Apr 2026	DEF 14A
09 Apr 2026	ARS
27 Mar 2026	PRE 14A
27 Mar 2026	8-K: Departure/Election of Directors or Officers; Compensation
19 Mar 2026	10-K
19 Mar 2026	8-K: Results of Operations and Financial Condition
27 Feb 2026	4
27 Feb 2026	4
27 Feb 2026	4